Atypical Neuroleptic Malignant Syndrome in Patients Treated with Aripiprazole and Clozapine: A Case-Series Study and Short Review

International Journal of Psychiatry in Medicine

Volumn 49, Issue 1, 2015, Pages 35-43

  Tseng, Ping Tao ^a   Chang, Yi Chung ^a   Chang, Chih Hua ^a   Wang, Hung Yu ^a   Cheng, Yu Shian ^a   Wu, Ching Kuan ^a   Chen, Yen Wen ^b   Chung, Weilun ^a  

^a Tsyr Huey (Loving) Mental Hospital   (Taiwan)

^b E DA HOSPITAL   (Taiwan)

Author keywords

aripiprazole; atypical NMS; case series; clozapine; combination therapy; drug drug interaction; massive creatine kinase elevation; neuroleptic malignant syndrome (NMS)

Indexed keywords

ALANINE AMINOTRANSFERASE; ARIPIPRAZOLE; ASPARTATE AMINOTRANSFERASE; CLOZAPINE; CREATINE KINASE; FLUOXETINE; OLANZAPINE; RISPERIDONE; SULPIRIDE; VALPROIC ACID; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUDITORY HALLUCINATION; CASE REPORT; CASE STUDY; CONSCIOUSNESS DISORDER; CREATINE KINASE BLOOD LEVEL; DELIRIUM; DELUSION; DRUG WITHDRAWAL; DYSTONIA; FEMALE; FEVER; HAND TREMOR; HUMAN; INCONTINENCE; KYPHOSIS; LEUKOCYTOSIS; MALE; MIDDLE AGED; MUSCLE RIGIDITY; MUTISM; NEUROLEPTIC MALIGNANT SYNDROME; PSYCHOSIS; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; STUPOR; TACHYCARDIA; BLOOD; DOSE RESPONSE; DRUG COMBINATION; DRUG SUBSTITUTION; ENZYMOLOGY; HOSPITALIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; PSYCHOLOGY; PSYCHOTIC DISORDERS;

ADULT; ARIPIPRAZOLE; CLOZAPINE; CREATINE KINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HOSPITALIZATION; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; PIPERAZINES; PSYCHOTIC DISORDERS; QUINOLONES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84965185753     PISSN: 00912174     EISSN: 15413527     Source Type: Journal    
DOI: 10.2190/PM.49.1.c     Document Type: Review

References (32)

1. Tural U, Onder E,. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death. Psychiatry and Clinical Neuroscience 2010; 64 (1): 79-87. doi: 10.1111/j.1440-1819.2009.02042.x.
2. Lazarus A, Mann SC, Caroff SN,. The neuroleptic malignant syndrome and related condition, Washington, DC: American Psychiatric Press, 1989.
3. Viejo LF, Morales V, Punal P, Perez JL, Sancho RA,. Risk factors in neuroleptic malignant syndrome. A case-control study. Acta Psychiatrica Scandinavica 2003; 107 (1): 45-49.
4. Pelonero AL, Levenson JL, Pandurangi AK,. Neuroleptic malignant syndrome: A review. Psychiatric Services 1998; 49 (9): 1163-1172.
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th. Washington, DC: American Psychiatric Publishing, 2000.
6. Picard LS, Lindsay S, Strawn JR, Kaneria RM, Patel NC, Keck PE Jr,. Atypical neuroleptic malignant syndrome: Diagnostic controversies and considerations. Phar-macotherapy 2008; 28 (4): 530-535. doi: 10.1592/phco.28.4.530.
7. Margetic B, Aukst-Margetic B,. Neuroleptic malignant syndrome and its controversies. Pharmacoepidemiologic Drug Safety 2010; 19 (5): 429-435. doi: 10.1002/pds.1937.
8. Bhanushali MJ, Tuite PJ,. The evaluation and management ofpatients with neuroleptic malignant syndrome. Neurology Clinics 2004; 22 (2): 389-411. doi: 10.1016/j.ncl.2003. 12.006.
9. Friedman JH, Feinberg SS, Feldman RG,. A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal. Journal ofthe American Medical Association 1985; 254 (19): 2792-2795.
10. Simpson DM, Davis GC,. Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine. American Journal of Psychiatry 1984; 141 (6): 796-797.
11. Swainston Harrison T, Perry CM,. Aripiprazole: A review of its use in schizophrenia and schizoaffective disorder. Drugs 2004; 64 (15): 1715-1736.
12. Inoue A, Miki S, Seto M, Kikuchi T, Morita S, Ueda H, Misu Y, Nakata Y,. Ari-piprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. European Journal of Pharmacology 1997; 321 (1): 105-111.
13. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T,. Aripiprazole in the treatment of schizophrenia: Safety and toler-ability inshort-term, placebo-controlled trials. Schizophrenia Research 2003; 61 (2-3): 123-136.
14. Karunakaran K, Tungaraza TE, Harborne GC,. Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia? Journal of Psychopharmacology 2007; 21 (4): 453-456. doi: 10.1177/0269881106068289.
15. Englisch S, Zink M,. Combined antipsychotic treatment involving clozapine and aripiprazole. Progress in Neuropsychopharmacologic Biology and Psychiatry 2008; 32 (6): 1386-1392. doi: 10.1016/j.pnpbp.2008.02.010.
16. Chang JS, Ahn YM, Park HJ, Lee KY, Kim SH, Kang UG, Kim YS,. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: An 8-week, randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 2008; 69 (5): 720-731.
17. Spalding S, Alessi NE, Radwan K,. Aripiprazole and atypical neuroleptic malignant syndrome. Journal of the American Academy ofChild and Adolescent Psychiatry 2004; 43 (12): 1457-1458. doi: 10.1097/01.chi.0000142277.95052.94.
18. Srephichit S, Sanchez R, Bourgeois JA,. Neuroleptic malignant syndrome and aripipra-zole in an antipsychotic-naive patient. Journal of Clinical Psychopharmacology 2006; 26 (1): 94-95.
19. Rodriguez OP, Dowell MS,. A case report of neuroleptic malignant syndrome without fever in a patient given aripiprazole. Journal ofthe Oklahoma State Medical Association 2006; 99 (7): 435-438.
20. Dassa D, Drai-Moog D, Samuelian JC,. Neuroleptic malignant syndrome with the addition of aripiprazole to clozapine. Progress in Neuropsychopharmacologic Biology and Psychiatry 2010; 34 (2): 427-428. doi: 10.1016/j.pnpbp.2009.12.022.
21. Tollefson GD, Dellva MA, Mattler CA, Kane JM, Wirshing DA, Kinon BJ,. Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group. Journal of Clinical Psychopharmacology 1999; 19 (5): 435-443.
22. Sachdev PS,. A rating scale for neuroleptic malignant syndrome. Psychiatry Research 2005; 135 (3): 249-256. doi: 0.1016/j.psychres.2005.05.003.
23. Trollor JN, Chen X, Sachdev PS,. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009; 23 (6): 477-492. doi: 10.2165/00023210200923060-00003.
24. Wren P, Frizzell LA, Keltner NL, Wright AV,. Three potentially fatal adverse effects of psychotropic medications. Perspectives in Psychiatric Care 2003; 39 (2): 75-81.
25. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T,. Neuroleptic malignant syndrome and atypical antipsychotic drugs. Journal of Clinical Psychiatry 2004; 65 (4): 464-470.
26. Su YP, Chang CK, Hayes RD, Harrison S, Lee W, Broadbent M, Taylor D, Stewart R,. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatrica Scandinavica 2013. doi: 10.1111/ acps.12222.
27. Riala K, Lahti A, Anttila E, Rasanen P,. Aripiprazole-related severe neuroleptic malignant syndrome with deep coma and organic brain changes in an antipsychotic-naive adolescent boy. Journal of Clinical Psychopharmacology 2013; 33 (1): 126-127. doi: 10.1097/01.jcp.0000426179.81948.3f.
28. Chen YT, Su KP, Chang JP,. Early detection and management of atypical neuro-leptic malignant syndrome secondary to aripiprazole. Schizophrenia Research 2011; 132 (1): 97-98. doi: 10.1016/j.schres.2011.07.005.
29. Fischer V, Vogels B, Maurer G, Tynes RE,. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. Journal of Pharmacologic Experimental Therapy 1992; 260 (3): 1355-1360.
30. Dragovic S, Gunness P, Ingelman-Sundberg M, Vermeulen NP, Commandeur JN,. Characterization of human cytochrome P450s involved in the bioactivation of clozapine. Drug Metabolism Disposition 2013; 41 (3): 651-658. doi: 10.1124/dmd.112. 050484.
31. Spina E, de Leon J,. Metabolic drug interactions with newer antipsychotics: A comparative review. Basic Clinical Pharmacology and Toxicology 2007; 100 (1): 4-22. doi: 10.1111/j.1742-7843.2007.00017.x.
32. Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR,. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: Identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. Journal of Pharmacologic Experimental Therapy 2005; 315 (3): 1278-1287. doi: 10.1124/jpet.105.092155.